Modafinil analogues acting as DRIs include both drugs similar to modafinil that affect dopamine without causing stimulant effects (atypical modafinil-like non-psychostimulant DRIs) such as flmodafinil and JJC8-016 and drugs that affect dopamine in a way similar to cocaine (classical or typical cocaine-like DRIs) such as JJC8-088. Besides their potential medical use, modafinil analogues, including adrafinil, flmodafinil, fladrafinil, and modafiendz, are also sold online as substances that are believed to improve cognitive functions such as memory and focus (nootropics or "cognitive enhancers").[1][9][10][11]
^ abcdefSalamone JD, Correa M (January 2024). "The Neurobiology of Activational Aspects of Motivation: Exertion of Effort, Effort-Based Decision Making, and the Role of Dopamine". Annual Review of Psychology. 75 (1): 1–32. doi:10.1146/annurev-psych-020223-012208. hdl:10234/207207. PMID37788571.
^Treadway MT, Salamone JD (2022). "Vigor, Effort-Related Aspects of Motivation and Anhedonia". Anhedonia: Preclinical, Translational, and Clinical Integration. Current Topics in Behavioral Neurosciences. Vol. 58. Cham. pp. 325–353. doi:10.1007/7854_2022_355. ISBN978-3-031-09682-2. PMID35505057.{{cite book}}: CS1 maint: location missing publisher (link)
^ abcdSchifano F, Catalani V, Sharif S, Napoletano F, Corkery JM, Arillotta D, et al. (April 2022). "Benefits and Harms of 'Smart Drugs' (Nootropics) in Healthy Individuals". Drugs. 82 (6): 633–647. doi:10.1007/s40265-022-01701-7. hdl:2299/25614. PMID35366192. [Modafinil] is widely available for online purchase [105] and it is of interest that a range of modafinil derivatives are actively being discussed on web fora, including: adrafinil, fladrafinil, flmodafinil, and N-methyl-4,4′-difluoro-modafinil [8]. Finally, the modafinil R-enantiomer armodafinil, which is being used to improve wakefulness in patients with excessive sleepiness [106], is currently the subject of an anecdotal debate relating to its properties as a [cognitive enhancer] [107].
^ abNapoletano F, Schifano F, Corkery JM, Guirguis A, Arillotta D, Zangani C, et al. (2020). "The Psychonauts' World of Cognitive Enhancers". Frontiers in Psychiatry. 11: 546796. doi:10.3389/fpsyt.2020.546796. PMC7516264. PMID33024436. 2-{[bis(4-fluorophenyl)methyl]sulfinyl}-N-methylacetamide is the bis-fluoro-N-methyl analogue of the substance modafinil and is currently marketed by online sellers as a nootropic substance called 'modafiendz'.
^ abDowling G, Kavanagh PV, Talbot B, O'Brien J, Hessman G, McLaughlin G, et al. (March 2017). "Outsmarted by nootropics? An investigation into the thermal degradation of modafinil, modafinic acid, adrafinil, CRL-40,940 and CRL-40,941 in the GC injector: formation of 1,1,2,2-tetraphenylethane and its tetra fluoro analogue"(PDF). Drug Testing and Analysis. 9 (3): 518–528. doi:10.1002/dta.2142. PMID27928893. 2-[(Diphenylmethyl)sulfinyl]acetamide (modafinil) is commonly prescribed for the treatment of narcolepsy and increasing popularity and off-label use as a cognitive enhancer resulted in a reputation as an intelligence boosting 'wonder drug'. Common alternatives available from online shops and other retail outlets include 2-[(diphenylmethyl)sulfinyl]-N-hydroxyacetamide (adrafinil), 2-([bis(4-fluorophenyl)methyl]sulfinyl)acetamide (CRL-40,940), 2-([bis(4-fluorophenyl)methyl]sulfinyl)-N-hydroxyacetamide (CRL-40,941) and N-methyl-4,4-difluoro-modafinil (modafiendz), respectively. [...] CRL-40,941 and modafiendz are also wakefulness promoting agents and related to modafinil and adrafinil (Figure 1).
^Lee KH, Fant AD, Guo J, Guan A, Jung J, Kudaibergenova M, et al. (September 2021). "Toward Reducing hERG Affinities for DAT Inhibitors with a Combined Machine Learning and Molecular Modeling Approach". J Chem Inf Model. 61 (9): 4266–4279. doi:10.1021/acs.jcim.1c00856. PMC9593962. PMID34420294. From this validation set of DAT inhibitors, we noticed that a pair of analogues with similar chemical structures, JJC8-01646 and JJC8-08813 (Tanimoto similarity = 0.62, Figure S6), have opposite trends of affinities at DAT and hERG. JJC8-088 has ~90-fold higher affinity than JJC8-016 at DAT (Ki = 2.6 and 234.4 nM, respectively), but has ~2-fold lower affinity than JJC8-016 at hERG (IC50 = 0.13 and 0.06 μM, respectively).
^ abcdeKalaba P, Ilić M, Aher NY, Dragačević V, Wieder M, Zehl M, et al. (January 2020). "Structure-Activity Relationships of Novel Thiazole-Based Modafinil Analogues Acting at Monoamine Transporters". J Med Chem. 63 (1): 391–417. doi:10.1021/acs.jmedchem.9b01938. PMID31841637.
^Sase A, Aher YD, Saroja SR, Ganesan MK, Sase S, Holy M, et al. (March 2016). "A heterocyclic compound CE-103 inhibits dopamine reuptake and modulates dopamine transporter and dopamine D1-D3 containing receptor complexes". Neuropharmacology. 102: 186–196. doi:10.1016/j.neuropharm.2015.07.039. PMID26407764.
^Saroja SR, Aher YD, Kalaba P, Aher NY, Zehl M, Korz V, et al. (October 2016). "A novel heterocyclic compound targeting the dopamine transporter improves performance in the radial arm maze and modulates dopamine receptors D1-D3". Behav Brain Res. 312: 127–137. doi:10.1016/j.bbr.2016.06.011. PMID27288589.
^Kristofova M, Aher YD, Ilic M, Radoman B, Kalaba P, Dragacevic V, et al. (May 2018). "A daily single dose of a novel modafinil analogue CE-123 improves memory acquisition and memory retrieval". Behav Brain Res. 343: 83–94. doi:10.1016/j.bbr.2018.01.032. PMID29410048.
^Hussein AM, Aher YD, Kalaba P, Aher NY, Dragačević V, Radoman B, et al. (August 2017). "A novel heterocyclic compound improves working memory in the radial arm maze and modulates the dopamine receptor D1R in frontal cortex of the Sprague-Dawley rat". Behav Brain Res. 332: 308–315. doi:10.1016/j.bbr.2017.06.023. PMID28629964.
^"Cinfenine". PubChem. Retrieved October 20, 2024.
^ abSalamone JD, Rotolo RA, Murray F, McNamara B, Presby RE, Yang JH, et al. (November 5, 2018). 323.04 / AAA17 - The novel atypical dopamine transport inhibitors CT-005094 and CT-005404 reverse the effort-related motivational effects of the dopamine depleting agent tetrabenazine. Neuroscience 2018. Society for Neuroscience. The present studies focused on recently synthesized atypical DAT inhibitors, CT-005094 and CT-005404. These compounds bind to DAT with high selectivity relative to the serotonin and norepinephrine transporters, and can elevate extracellular levels of DA as measured by microdialysis without stimulating DA release. In the present studies, CT-005094 and CT-005404 were assessed for their ability to reverse the effort-related motivational effects of tetrabenazine. Rats were tested using the fixed ratio 5/chow feeding choice test. Tetrabenazine (1.0 mg/kg) shifted choice behaviour, decreasing lever pressing and increasing chow intake. CT-005094 was co-administered at doses ranging from 2.0-16.0 mg/kg IP, and the 8.0 mg/kg dose partially but significantly reversed the effects of tetrabenazine. CT-005404 was orally active, and reversed the effects of tetrabenazine in the dose range of 15.0-30.0 mg/kg PO. Atypical DAT inhibitors such as CT-005094 and CT-005404 offer potential as a new avenue for drug treatment of motivational dysfunctions in humans.
^ abMoscoso M, Sanchez S (2019). "Society for Neuroscience – 48th Annual Meeting. San Diego, California, USA – November 3–7, 2018". Drugs of the Future. 44 (1): 93. doi:10.1358/dof.2019.44.1.2954217. The assessment of two other modafinil-based atypical DAT inhibitors, CT-005404 and CT-0050904, in the reversal of the [...]
^Rotolo RA, Presby RE, Tracy O, Asar S, Yang JH, Correa M, et al. (February 2021). "The novel atypical dopamine transport inhibitor CT-005404 has pro-motivational effects in neurochemical and inflammatory models of effort-based dysfunctions related to psychopathology". Neuropharmacology. 183: 108325. doi:10.1016/j.neuropharm.2020.108325. PMID32956676.
^Konofal E (August 2024). "From past to future: 50 years of pharmacological interventions to treat narcolepsy". Pharmacol Biochem Behav. 241: 173804. doi:10.1016/j.pbb.2024.173804. PMID38852786. Among these advancements is lauflumide (NLS-4), a forward step from earlier substances initially envisioned by Lafon Laboratories yet not realized (Dowling et al., 2017). Developed by NLS Pharmaceutics AG, lauflumide represents a cutting-edge development as a selective dopamine reuptake inhibitor. It is an enantiomerically pure R-isomer, with an enantiomeric excess exceeding 95 %, of a bis(p-fluoro) phenyl ring-substituted derivative of modafinil, showcasing the innovative work of inventor Eric Konofal (USPTO Patent 2017, US9637447B2) (Konofal, 2017). Unlike modafinil, which induces hepatic enzyme activity with repeated doses, lauflumide does not act as an inducer of cytochrome P450 (CYP) enzymes, including CYP3A4/5. In mouse models, lauflumide has demonstrated potent wake-promoting effects without the risk of hypersomnia rebound (unpublished data). Moreover, the recovery sleep following lauflumide administration is marked by a reduced amount of NREM sleep and delta wave activity, indicating a decreased need for recovery sleep despite extended periods of wakefulness induced by the drug (Luca et al., 201 ).
^Luca G, Bandarabadi M, Konofal E, Lecendreux M, Ferrié L, Figadère B, et al. (2018). "Lauflumide (NLS-4) Is a New Potent Wake-Promoting Compound". Front Neurosci. 12: 519. doi:10.3389/fnins.2018.00519. PMC6104159. PMID30158846. Preliminary findings suggest that NLS-4 is a selective dopamine reuptake inhibitor, blocking (83%) dopamine transporter (DAT), higher than methylphenidate and without deleterious effects on peripheral adrenergic systems involved in hypertension (Study 100014859 CEREP 20/03/14, unpublished data).
^ abHernandez GC, Gopinath A, Okorom A, Khoshbouei H, Newman AH (2024). "Fluorescently Labelled Ligand Allow Detection of DAT in Human and Mouse Peripheral Blood Monocytes by Flow Cytometry". ASPET 2024 Annual Meeting Abstract - Neuropharmacology. American Society for Pharmacology and Experimental Therapeutics. p. 520. doi:10.1124/jpet.520.939780.
^Dunn D, Hostetler G, Iqbal M, Messina-McLaughlin P, Reiboldt A, Lin YG, et al. (March 2012). "Wake-promoting agents: search for next generation modafinil: part I". Bioorg Med Chem Lett. 22 (6): 2312–2314. doi:10.1016/j.bmcl.2011.12.099. PMID22264475.
^Dunn D, Hostetler G, Iqbal M, Messina-McLaughlin P, Reiboldt A, Lin YG, et al. (March 2012). "Wake-promoting agents: search for next generation modafinil: part II". Bioorg Med Chem Lett. 22 (6): 2315–2317. doi:10.1016/j.bmcl.2012.01.064. PMID22341942.
^Dunn D, Hostetler G, Iqbal M, Marcy VR, Lin YG, Jones B, et al. (June 2012). "Wake promoting agents: search for next generation modafinil, lessons learnt: part III". Bioorg Med Chem Lett. 22 (11): 3751–3753. doi:10.1016/j.bmcl.2012.04.031. PMID22546675.
^Louvet P, Schweizer D, Gourdel ME, Riguet E, Yue C, Marcy VR, et al. (August 2012). "Wake-promoting agents: search for next generation modafinil: part IV". Eur J Med Chem. 54: 949–951. doi:10.1016/j.ejmech.2012.05.038. PMID22749190.
^Lesur B, Lin YG, Marcy VR, Aimone LD, Gruner J, Bacon ER, et al. (March 2013). "Aryl-heteroaryl derivatives as novel wake-promoting agents". Chem Biol Drug Des. 81 (3): 429–432. doi:10.1111/cbdd.12083. PMID23110414.
^Kalaba P, Aher NY, Ilić M, Dragačević V, Wieder M, Miklosi AG, et al. (November 2017). "Heterocyclic Analogues of Modafinil as Novel, Atypical Dopamine Transporter Inhibitors". J Med Chem. 60 (22): 9330–9348. doi:10.1021/acs.jmedchem.7b01313. PMID29091428.